<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066322</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-26</org_study_id>
    <nct_id>NCT04066322</nct_id>
  </id_info>
  <brief_title>Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment</brief_title>
  <acronym>RMPanNET</acronym>
  <official_title>Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment: Real World Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy and tolerability of surgery in selecting patients who
      can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and
      liver metastasis after induction systemic treatment. The willing of participants decide who
      receive surgery and who will continue to receive standard systemic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      system treatments of metastatic PanNET include SSA, sunitinib, mTOR inhibitor and
      chemotherapy. For patients achieved PR/SD after system treatment, resection of primary tumor
      and metastasis maybe a better way to decline tumor burden and get longer survival. this real
      world study is focused on this group of patients with metastatic PanNET, and to evaluate the
      efficacy and tolerability of surgery in selecting patients who can benefit from the
      synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after
      induction systemic treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2019</start_date>
  <completion_date type="Anticipated">July 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Postoperative morbidity</measure>
    <time_frame>Up to 90 days after operation</time_frame>
    <description>Including pancreatic fistula, biliary fistula, hemorrhage, wound infection, delayed gastric emptying, reoperation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of Postoperative mortality</measure>
    <time_frame>Up to 90 days after operation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>number of Patients die from any cause during 90 days after operation</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>progression-free survival in subgroup analysis</measure>
    <time_frame>5 years</time_frame>
    <description>liver metastasis type, grade, extrahepatic metastasis</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Metastases</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>system treatment</arm_group_label>
    <description>Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>system treatment and Surgery</arm_group_label>
    <description>Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>system treatment and surgery</intervention_name>
    <description>to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.</description>
    <arm_group_label>system treatment and Surgery</arm_group_label>
    <other_name>resection of primary and metastatic tumors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>system treatment</intervention_name>
    <description>to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.</description>
    <arm_group_label>system treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with metastatic pancreatic neuroendocrine tumors in a tertiary referal center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy-proven neuroendocrine tumor

          2. primary site in pancreas

          3. Advanced disease with lymph node or distant metastases (N1, M1) cannot undergoing
             cytoreduction by surgery/local ablative therapy at the diagnosis

          4. curative intent of all therapies possible

          5. ECOG 0-2

        Exclusion Criteria:

          1. Undifferentiated neuroendocrine carcinoma or mixed neuroendocrine carcinoma secondary
             tumor

          2. functioning NET or advanced carcinoid heart disease

          3. part of hereditary syndrome, such as MEN1, VHL

          4. do not willing to receive systemic treatment

          5. diagnosed with other cancer within 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xianjun yu, MD</last_name>
    <phone>+86 21 64175590</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heli Gao</last_name>
    <phone>+86 21 64175590</phone>
    <email>gaoheli@fudanpci.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XianJun Yu, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
    <investigator>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

